secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0000950170-25-006992
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Biotherapeutics receives FDA clinical hold on EBVALLO and ATA3219 programs
--------------------------------------------------------------------------------

- FDA clinical hold on EBVALLO and ATA3219 studies due to GMP compliance issues at third-party manufacturer.
- New patient enrollment paused; currently enrolled patients who may benefit can continue treatment.
- Clinical hold linked to inadequately addressed GMP issues from Jan 16 CRL for EBVALLO.
- Atara's second manufacturer FDB in Thousand Oaks unaffected; remains part of long-term strategy.
- FDA committed to working expeditiously with Atara to resolve clinical hold.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017025006992/0000950170-25-006992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017025006992/atra-20250121.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-006992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer